TEMPUS FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Tempus Investors of the August 11th Deadline and Urges Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. for allegedly failing to disclose critical information regarding its financial practices and operations, leading to significant losses for investors [1][3][4]. Group 1: Allegations Against Tempus - The complaint alleges that Tempus inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [3]. - Concerns were raised about the credibility of Tempus' joint venture with SoftBank, suggesting it appeared to involve "round-tripping" capital to create revenue [3]. - The business model of Tempus-acquired Ambry was criticized for potentially unethical billing practices, risking scrutiny and sustainability [3]. - AstraZeneca's reduced financial commitments to Tempus were questioned due to a "pass-through payment" arrangement, indicating operational weaknesses [3]. - The issues highlighted in the lawsuit suggest significant weaknesses in Tempus' core operations and revenue prospects [3]. Group 2: Impact of the Allegations - Following the release of a report by Spruce Point Capital Management that raised multiple concerns about Tempus' management and financial reporting, the company's stock price fell by $12.67, or 19.23%, from $65.87 to $53.20 per share [4][5]. - The report indicated that Tempus' actual AI capabilities were overstated and that there were signs of aggressive accounting practices [4]. - The involvement of board members and executives with troubled companies that had restated financial results was also noted as a red flag [4].